101 related articles for article (PubMed ID: 25514384)
1. Pramipexole protects dopaminergic neurons through paraplegin against 6-hydroxydopamine.
Kim MK; Park HS; Cho JH; Kim GS; Won C
Neuroreport; 2015 Jan; 26(2):74-80. PubMed ID: 25514384
[TBL] [Abstract][Full Text] [Related]
2. Dopamine D3 receptor-modulated neuroprotective effects of lisuride.
Kim M; Lee S; Cho J; Kim G; Won C
Neuropharmacology; 2017 May; 117():14-20. PubMed ID: 28131770
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
5. Myricitrin Ameliorates 6-Hydroxydopamine-Induced Dopaminergic Neuronal Loss in the Substantia Nigra of Mouse Brain.
Kim HD; Jeong KH; Jung UJ; Kim SR
J Med Food; 2016 Apr; 19(4):374-82. PubMed ID: 26991235
[TBL] [Abstract][Full Text] [Related]
6. Dopamine D1 receptor agonism induces dynamin related protein-1 inhibition to improve mitochondrial biogenesis and dopaminergic neurogenesis in rat model of Parkinson's disease.
Mishra A; Singh S; Tiwari V; Bano S; Shukla S
Behav Brain Res; 2020 Jan; 378():112304. PubMed ID: 31626851
[TBL] [Abstract][Full Text] [Related]
7. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
8. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures.
Ling ZD; Robie HC; Tong CW; Carvey PM
J Pharmacol Exp Ther; 1999 Apr; 289(1):202-10. PubMed ID: 10087005
[TBL] [Abstract][Full Text] [Related]
9. Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity.
Imamura K; Takeshima T; Nakaso K; Ito S; Nakashima K
Neurosci Lett; 2008 Aug; 440(2):97-102. PubMed ID: 18555604
[TBL] [Abstract][Full Text] [Related]
10. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection.
Le WD; Jankovic J; Xie W; Appel SH
J Neural Transm (Vienna); 2000; 107(10):1165-73. PubMed ID: 11129106
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
[TBL] [Abstract][Full Text] [Related]
12. Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine.
Vu TQ; Ling ZD; Ma SY; Robie HC; Tong CW; Chen EY; Lipton JW; Carvey PM
J Neural Transm (Vienna); 2000; 107(2):159-76. PubMed ID: 10847557
[TBL] [Abstract][Full Text] [Related]
13. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity.
Izumi Y; Sawada H; Yamamoto N; Kume T; Katsuki H; Shimohama S; Akaike A
Eur J Pharmacol; 2007 Feb; 557(2-3):132-40. PubMed ID: 17161393
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effects of neurokinin receptor one in dopaminergic neurons are mediated through Akt/PKB cell signaling pathway.
Chu JM; Chen LW; Chan YS; Yung KK
Neuropharmacology; 2011 Dec; 61(8):1389-98. PubMed ID: 21907219
[TBL] [Abstract][Full Text] [Related]
15. Motivational properties of D2 and D3 dopamine receptors agonists and cocaine, but not with D1 dopamine receptors agonist and L-dopa, in bilateral 6-OHDA-lesioned rat.
Zengin-Toktas Y; Authier N; Denizot H; Chassain C; Hafidi A; Llorca PM; Durif F
Neuropharmacology; 2013 Jul; 70():74-82. PubMed ID: 23347953
[TBL] [Abstract][Full Text] [Related]
16. Full and partial peroxisome proliferation-activated receptor-γ agonists, but not δ agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression.
Sadeghian M; Marinova-Mutafchieva L; Broom L; Davis JB; Virley D; Medhurst AD; Dexter DT
J Neuroimmunol; 2012 May; 246(1-2):69-77. PubMed ID: 22498097
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Protective Role of Multifunctional Dopamine Agonist D-512 Against Oxidative Stress Produced by Depletion of Glutathione in PC12 Cells: Implication in Neuroprotective Therapy for Parkinson's Disease.
Voshavar C; Shah M; Xu L; Dutta AK
Neurotox Res; 2015 Nov; 28(4):302-18. PubMed ID: 26201265
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons.
Hall ED; Andrus PK; Oostveen JA; Althaus JS; VonVoigtlander PF
Brain Res; 1996 Dec; 742(1-2):80-8. PubMed ID: 9117424
[TBL] [Abstract][Full Text] [Related]
19. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
20. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
Wachtel SR; Hu XT; Galloway MP; White FJ
Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
